Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biotechnology
Ginkgo Bioworks makes 3 acquisitions
by Aayushi Pratap
March 4, 2024
| A version of this story appeared in
Volume 102, Issue 7
Boston-based Ginkgo Bioworks has added three companies to its portfolio. The first is Cambridge, Massachusetts–based Proof Diagnostics, cofounded by Feng Zhang of the Broad Institute of MIT and Harvard in 2020. The firm is building CRISPR-based COVID-19 molecular tests. Next is New York–based Patch Biosciences, which is using machine learning to engineer gene therapies. Ginkgo’s last buy, Boston-based Reverie Labs, uses artificial intelligence and machine learning to accelerate drug discovery. Ginkgo did not disclose the cost of the acquisitions.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter